E Fund Management (Hong Kong) Co., Ltd. Zai Lab LTD Transaction History

E Fund Management (Hong Kong) Co., Ltd.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 21, 2023	BUY	$30.21 - $48.1 $695,252 - $1.11 Million	23,014 Added 38.63%	82,587 $2.75 Million
Q4 2022 Feb 01, 2023	SELL	$22.28 - $38.71 $378 - $658	-17 Reduced 0.03%	59,573 $1.83 Million
Q2 2022 Jul 13, 2022	BUY	$23.14 - $49.68 $332,683 - $714,249	14,377 Added 31.8%	59,590 $2.07 Million
Q1 2022 Apr 12, 2022	BUY	$27.77 - $64.4 $728,962 - $1.69 Million	26,250 Added 138.43%	45,213 $1.94 Million
Q4 2021 Feb 07, 2022	SELL	$54.9 - $105.21 $21,411 - $41,031	-390 Reduced 2.02%	18,963 $1.19 Million
Q2 2021 Jul 27, 2021	BUY	$125.11 - $180.0 $60,928 - $87,660	487 Added 2.58%	19,353 $3.43 Million
Q1 2021 Apr 13, 2021	BUY	$126.27 - $191.71 $82,833 - $125,761	656 Added 3.6%	18,866 $2.52 Million
Q4 2020 Jan 05, 2021	BUY	$81.94 - $135.34 $312,273 - $515,780	3,811 Added 26.47%	18,210 $2.46 Million
Q3 2020 Oct 09, 2020	BUY	$73.3 - $89.48 $287,189 - $350,582	3,918 Added 37.38%	14,399 $1.2 Million
Q2 2020 Jul 06, 2020	BUY	$48.82 - $82.53 $113,750 - $192,294	2,330 Added 28.59%	10,481 $861,000
Q1 2020 May 13, 2020	BUY	$39.1 - $62.9 $318,704 - $512,697	8,151 New	8,151 $420,000

125

49.6M

223K

588K

Ticker ZLAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,908,704
Market Cap $2.72B
Description
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA f...

Get notified when there are updates to the investment portfolio of E Fund Management (Hong Kong) Co., Ltd., based on Form 13F filings with the SEC.

Stay updated on E Fund Management (Hong Kong) Co., Ltd. with notifications on news.